tradingkey.logo

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide

ReutersDec 16, 2025 12:09 PM

- Monte Rosa Therapeutics Inc GLUE.O:

  • MONTE ROSA THERAPEUTICS ANNOUNCES COMPELLING CLINICAL ACTIVITY OF MRT-2359 IN COMBINATION WITH ENZALUTAMIDE IN HEAVILY PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITH ANDROGEN RECEPTOR MUTATIONS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI